Rafferty Asset Management
DNTH icon

Rafferty Asset Management’s Dianthus Therapeutics DNTH Stock Holding History

Rafferty Asset Management’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.62M Sell
31,221
-26,654
-46% -$1.54M 0.01% 555
2025
Q4 		$2.39M Buy
57,875
+40,544
+234% +$1.57M 0.01% 610
2025
Q3 		$682K Sell
17,331
-11,191
-39% -$286K ﹤0.01% 856
2025
Q2 		$531K Buy
28,522
+4,650
+19% +$87.2K ﹤0.01% 874
2025
Q1 		$433K Sell
23,872
-4,587
-16% -$101K ﹤0.01% 896
2024
Q4 		$620K Sell
28,459
-2,188
-7% -$56.3K ﹤0.01% 873
2024
Q3 		$839K Buy
+30,647
New +$854K ﹤0.01% 833

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Rafferty Asset Management's DNTH Position: Q1 2026 in Review

Rafferty Asset Management reduced its Dianthus Therapeutics (DNTH) stake by 46% in Q1 2026, selling an estimated $1.54M and leaving 31,221 shares worth $2.62M. The position accounts for 0.01% of the portfolio, ranked #555.

Rafferty Asset Management first reported a position in DNTH in Q3 2024 and has held it in 7 quarters since. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • Rafferty Asset Management held 31,221 shares of Dianthus Therapeutics worth $2.62M as of Q1 2026.
  • Rafferty Asset Management sold 26,654 Dianthus Therapeutics shares in Q1 2026, an estimated $1.54M.
  • Dianthus Therapeutics made up 0.01% of Rafferty Asset Management's portfolio in Q1 2026, its #555 holding.
  • Rafferty Asset Management first reported a position in Dianthus Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on Rafferty Asset Management's 13F filing for Q1 2026, filed 15 May 2026.